Publications searcher

The science produced by our scientists is very important. In 2024, 1,501 papers were published in scientific journals with an average impact factor of over 7.13 points.

Phase I assessment of new mechanism-based pharmacodynamic biomarkers for MLN8054, a small-molecule inhibitor of Aurora A kinase.

PMID: 21148750
Journal: CANCER RESEARCH
Year: 2011
Reference: Cancer Res. 2011 Feb 1;71(3):675-85. Epub 2010 Dec 10.
Impact factor: 8.234
Publication type: Paper in international publication
Authors: Stringer, Bradley, Tirrell, Stephen, Veiby, Ole Petter, Venkatakrishnan, Karthik, Galvin, Katherine, Manfredi, Mark, Ecsedy, Jeffrey A, Simpson, Chris, Silverman, Lee, Pappas, Jodi et al.
DOI: 10.1158/0008-5472.CAN-10-1030

Phase I assessment of new mechanism-based pharmacodynamic biomarkers for MLN8054, a small-molecule inhibitor of Aurora A kinase.

PMID: 21148750
Journal: CANCER RESEARCH
Year: 2011
Reference: Cancer Res. 2011 Feb 1;71(3):675-85. Epub 2010 Dec 10.
Impact factor:
Publication type: Paper in international publication
Authors: Andreu, Jordi; Bowman, Douglas; Burris, Howard; Cervantes, Andres; Chakravarty, Arijit; Cohen, Roger B; Danaee, Hadi; Dees, E Claire; Ecsedy, Jeffrey A; Elez, Elena et al.
DOI: 10.1158/0008-5472.CAN-10-1030

Phase I Pharmacokinetic and Pharmacodynamic Dose-Escalation Study of RG7160 (GA201), the First Glycoengineered Monoclonal Antibody Against the Epidermal Growth Factor Receptor, in Patients With Advanced Solid Tumors.

PMID: 21900113
Journal: JOURNAL OF CLINICAL ONCOLOGY
Year: 2011
Reference: J Clin Oncol. 2011 Oct 1;29(28):3783-90. Epub 2011 Sep 6.
Impact factor: 18.97
Publication type: Paper in international publication
Authors: , , , , , , , , , et al.
DOI: 10.1200/JCO.2011.34.8888

Phase I Pharmacokinetic and Pharmacodynamic Dose-Escalation Study of RG7160 (GA201), the First Glycoengineered Monoclonal Antibody Against the Epidermal Growth Factor Receptor, in Patients With Advanced Solid Tumors.

PMID: 21900113
Journal: JOURNAL OF CLINICAL ONCOLOGY
Year: 2011
Reference: J Clin Oncol. 2011 Oct 1;29(28):3783-90. Epub 2011 Sep 6.
Impact factor:
Publication type: Paper in international publication
Authors: ; ; ; ; ; ; ; ; ; et al.
DOI: 10.1200/JCO.2011.34.8888

Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity.

PMID: 21427062
Journal: ANNALS OF ONCOLOGY
Year: 2011
Reference: Ann Oncol. 2011 Dec;22(12):2646-53. Epub 2011 Mar 21.
Impact factor: 6.452
Publication type: Paper in international publication
Authors: , , , , , , , , , et al.
DOI: 10.1093/annonc/mdr023

Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity.

PMID: 21427062
Journal: ANNALS OF ONCOLOGY
Year: 2011
Reference: Ann Oncol. 2011 Dec;22(12):2646-53. Epub 2011 Mar 21.
Impact factor:
Publication type: Paper in international publication
Authors: ; ; ; ; ; ; ; ; ; et al.
DOI: 10.1093/annonc/mdr023

Phase II trial of induction irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for unresectable, locally advanced gastric and oesophageal-gastric junction adenocarcinoma.

PMID: 20198372
Journal: CANCER CHEMOTHERAPY AND PHARMACOLOGY
Year: 2011
Reference: Cancer Chemother Pharmacol. 2011 Jan;67(1):75-82. Epub 2010 Mar 3.
Impact factor: 2.759
Publication type: Paper in international publication
Authors: , , , , , , , , , et al.
DOI: 10.1007/s00280-010-1285-1

Phase II trial of induction irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for unresectable, locally advanced gastric and oesophageal-gastric junction adenocarcinoma.

PMID: 20198372
Journal: CANCER CHEMOTHERAPY AND PHARMACOLOGY
Year: 2011
Reference: Cancer Chemother Pharmacol. 2011 Jan;67(1):75-82. Epub 2010 Mar 3.
Impact factor:
Publication type: Paper in international publication
Authors: ; ; ; ; ; ; ; ; ; et al.
DOI: 10.1007/s00280-010-1285-1

Phase III dose-comparison study of glatiramer acetate for multiple sclerosis.

PMID: 21280077
Journal: ANNALS OF NEUROLOGY
Year: 2011
Reference: Ann Neurol. 2011 Jan;69(1):75-82. doi: 10.1002/ana.22316.
Impact factor: 10.746
Publication type: Paper in international publication
Authors: Damier, P, Luetic, G G, Vrech, C A, Dubois, B D P, Metz, L, Bar-Or, A, Bhan, V, Myles, M, Havrdova, E, Ehler, E et al.
DOI: 10.1002/ana.22316

Phase III dose-comparison study of glatiramer acetate for multiple sclerosis.

PMID: 21280077
Journal: ANNALS OF NEUROLOGY
Year: 2011
Reference: Ann Neurol. 2011 Jan;69(1):75-82. doi: 10.1002/ana.22316.
Impact factor:
Publication type: Paper in international publication
Authors: Absinta, Martina; Achiron, A; Agius, M; Antel, Jack; Arbizu, T; Arnold, Douglas L; Arnold, Douglas L; Arroyo, R; Bajenaru, O; Bar-Or, A et al.
DOI: 10.1002/ana.22316

Phenotypic variability of the kyphoscoliotic type of Ehlers-Danlos syndrome (EDS VIA): clinical, molecular and biochemical delineation.

PMID: 21699693
Journal: Orphanet Journal of Rare Diseases
Year: 2011
Reference: Orphanet J Rare Dis. 2011 Jun 23;6:46. doi: 10.1186/1750-1172-6-46.
Impact factor: 5.933
Publication type: Paper in international publication
Authors: Rohrbach, Marianne, Vandersteen, Anthony, Yis, Uluc, Serdaroglu, Gul, Ataman, Esra, Chopra, Maya, Garcia, Sixto, Jones, Kristi, Kariminejad, Ariana, Kraenzlin, Marius et al.
DOI: 10.1186/1750-1172-6-46

Phenotypic variability of the kyphoscoliotic type of Ehlers-Danlos syndrome (EDS VIA): clinical, molecular and biochemical delineation.

PMID: 21699693
Journal: Orphanet Journal of Rare Diseases
Year: 2011
Reference: Orphanet J Rare Dis. 2011 Jun 23;6:46. doi: 10.1186/1750-1172-6-46.
Impact factor:
Publication type: Paper in international publication
Authors: Ataman, Esra; Baumgartner, Matthias; Chopra, Maya; Garcia, Sixto; Giunta, Cecilia; Jones, Kristi; Kariminejad, Ariana; Kraenzlin, Marius; Marcelis, Carlo; Rohrbach, Marianne et al.
DOI: 10.1186/1750-1172-6-46

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer.

PMID: 21278786
Journal: ONCOGENE
Year: 2011
Reference: Oncogene. 2011 Jun 2;30(22):2547-57. doi: 10.1038/onc.2010.626. Epub 2011 Jan 31.
Impact factor: 7.414
Publication type: Paper in international publication
Authors: , , , , , , , , , et al.
DOI: 10.1038/onc.2010.626

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer.

PMID: 21278786
Journal: ONCOGENE
Year: 2011
Reference: Oncogene. 2011 Jun 2;30(22):2547-57. doi: 10.1038/onc.2010.626. Epub 2011 Jan 31.
Impact factor:
Publication type: Paper in international publication
Authors: ; ; ; ; ; ; ; ; ; et al.
DOI: 10.1038/onc.2010.626

PI3K Pathway in NSCLC.

PMID: 22655251
Journal: Frontiers in oncology
Year: 2011
Reference: Front Oncol. 2012 Jan 6;1:55. doi: 10.3389/fonc.2011.00055. eCollection 2011.
Impact factor: 0
Publication type: Review in international publication
Authors: Felip, Enriqueta, Martinez-Marti, Alex et al.
DOI: 10.3389/fonc.2011.00055

PI3K Pathway in NSCLC.

PMID: 22655251
Journal: Frontiers in oncology
Year: 2011
Reference: Front Oncol. 2012 Jan 6;1:55. doi: 10.3389/fonc.2011.00055. eCollection 2011.
Impact factor:
Publication type: Review in international publication
Authors: Felip, Enriqueta; Martinez-Marti, Alex et al.
DOI: 10.3389/fonc.2011.00055

[Pilot study on facial palsy correction with suture suspension].

PMID: 20227668
Journal: Acta otorrinolaringologica espanola
Year: 2011
Reference: Acta Otorrinolaringol Esp. 2011 Mar-Apr;62(2):161-3. doi: 10.1016/j.otorri.2010.01.011. Epub 2010 Mar 15.
Impact factor: 0
Publication type: Paper in national publication
Authors: Boemo, Rafael, Torrent, Lluisa, Knapper, Jennifer, Navarrete Alvaro, Maria Luisa et al.
DOI: 10.1016/j.otorri.2010.01.011

[Pilot study on facial palsy correction with suture suspension].

PMID: 20227668
Journal: Acta Otorrinolaringológica Española
Year: 2011
Reference: Acta Otorrinolaringol Esp. 2011 Mar-Apr;62(2):161-3. doi: 10.1016/j.otorri.2010.01.011. Epub 2010 Mar 15.
Impact factor:
Publication type: Paper in national publication
Authors: Boemo, Rafael; Knapper, Jennifer; Navarrete Alvaro, Maria Luisa; Torrent, Lluisa et al.
DOI: 10.1016/j.otorri.2010.01.011

Pilot study on the efficiency of the biostimulation with autologous plasma rich in platelet growth factors in otorhinolaryngology: otologic surgery (tympanoplasty type I).

PMID: 22084757
Journal: ISRN Surgery
Year: 2011
Reference: ISRN Surg. 2011;2011:451020. Epub 2011 Jun 20.
Impact factor:
Publication type: Letter or abstract
Authors: Navarrete Alvaro, Maria Luisa, Ortiz, N, Rodriguez, L, Boemo, R, Fuentes, J F, Mateo, A, Ortiz, P et al.
DOI: 10.5402/2011/451020

Pilot study on the efficiency of the biostimulation with autologous plasma rich in platelet growth factors in otorhinolaryngology: otologic surgery (tympanoplasty type I).

PMID: 22084757
Journal: ISRN Surgery
Year: 2011
Reference: ISRN Surg. 2011;2011:451020. Epub 2011 Jun 20.
Impact factor:
Publication type: Letter or abstract
Authors: Boemo, R; Fuentes, J F; Mateo, A; Navarrete Alvaro, Maria Luisa; Ortiz, N; Ortiz, P; Rodriguez, L et al.
DOI: 10.5402/2011/451020

Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.

PMID: 21571362
Journal: LANCET
Year: 2011
Reference: Lancet. 2011 May 21;377(9779):1760-9. Epub 2011 May 13.
Impact factor: 33.633
Publication type: Paper in international publication
Authors: Duarte, A, Glassberg, Marilyn K, Kardatzke, David, King, Talmadge E Jr, Lancaster, Lisa, Sahn, Steven A, Szwarcberg, Javier, Valeyre, Dominique, du Bois, Roland M, Agostini, C et al.
DOI: 10.1016/S0140-6736(11)60405-4

Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.

PMID: 21571362
Journal: LANCET
Year: 2011
Reference: Lancet. 2011 May 21;377(9779):1760-9. Epub 2011 May 13.
Impact factor:
Publication type: Paper in international publication
Authors: Acosta, O; Agostini, C; Albera, Carlo; Allen, J; Ancochea, J; Andrews, C; Antin-Ozerkis, D; Baughman, R; Bonnet, R; Bradford, Williamson Z et al.
DOI: 10.1016/S0140-6736(11)60405-4

[Pneumococcal pneumonia: epidemiological, diagnostic and therapeutic changes.]

PMID: 21396742
Journal: ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA
Year: 2011
Reference: Enferm Infecc Microbiol Clin. 2011 Apr;29(4):247-9. Epub 2011 Mar 10.
Impact factor: 1.656
Publication type: Editorial in national publication
Authors: , et al.
DOI: 10.1016/j.eimc.2011.01.005

[Pneumococcal pneumonia: epidemiological, diagnostic and therapeutic changes.]

PMID: 21396742
Journal: ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA
Year: 2011
Reference: Enferm Infecc Microbiol Clin. 2011 Apr;29(4):247-9. Epub 2011 Mar 10.
Impact factor:
Publication type: Editorial in national publication
Authors: ; et al.
DOI: 10.1016/j.eimc.2011.01.005

Publications

Publications searcher

Phase I assessment of new mechanism-based pharmacodynamic biomarkers for MLN8054, a small-molecule inhibitor of Aurora A kinase.

Phase I assessment of new mechanism-based pharmacodynamic biomarkers for MLN8054, a small-molecule inhibitor of Aurora A kinase.

Phase I Pharmacokinetic and Pharmacodynamic Dose-Escalation Study of RG7160 (GA201), the First Glycoengineered Monoclonal Antibody Against the Epidermal Growth Factor Receptor, in Patients With Advanced Solid Tumors.

Phase I Pharmacokinetic and Pharmacodynamic Dose-Escalation Study of RG7160 (GA201), the First Glycoengineered Monoclonal Antibody Against the Epidermal Growth Factor Receptor, in Patients With Advanced Solid Tumors.

Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity.

Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity.

Phase II trial of induction irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for unresectable, locally advanced gastric and oesophageal-gastric junction adenocarcinoma.

Phase II trial of induction irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for unresectable, locally advanced gastric and oesophageal-gastric junction adenocarcinoma.

Phase III dose-comparison study of glatiramer acetate for multiple sclerosis.

Phase III dose-comparison study of glatiramer acetate for multiple sclerosis.

Phenotypic variability of the kyphoscoliotic type of Ehlers-Danlos syndrome (EDS VIA): clinical, molecular and biochemical delineation.

Phenotypic variability of the kyphoscoliotic type of Ehlers-Danlos syndrome (EDS VIA): clinical, molecular and biochemical delineation.

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer.

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer.

PI3K Pathway in NSCLC.

PI3K Pathway in NSCLC.

[Pilot study on facial palsy correction with suture suspension].

[Pilot study on facial palsy correction with suture suspension].

Pilot study on the efficiency of the biostimulation with autologous plasma rich in platelet growth factors in otorhinolaryngology: otologic surgery (tympanoplasty type I).

Pilot study on the efficiency of the biostimulation with autologous plasma rich in platelet growth factors in otorhinolaryngology: otologic surgery (tympanoplasty type I).

Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.

Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.

[Pneumococcal pneumonia: epidemiological, diagnostic and therapeutic changes.]

[Pneumococcal pneumonia: epidemiological, diagnostic and therapeutic changes.]

Patronage:

Collaborating:

Accreditations: